Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | PDE6D | O43924 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13340251 | 1.00 | HPGD (0.38) | HPGDPDE6DTNKSEGFRADRA2A | |
| SCHEMBL13340297 | 1.00 | HPGD (0.38) | HPGDPDE6DTNKSEGFRADRA2A | |
| SCHEMBL13339215 | 0.93 | HPGD (0.34) | HPGD | |
| SCHEMBL13340302 | 0.93 | HSD17B3 (0.33) | HPGDPDE6DEGFRADRA2AADRA2B | |
| SCHEMBL13340268 | 0.92 | PDE6D (0.34) | HPGDPDE6DKDM4EALDH1A1MAPT | |
| SCHEMBL13340212 | 0.90 | HPGD (0.35) | HPGD | |
| SCHEMBL13340226 | 0.90 | HPGD (0.35) | HPGDPDE6D | |
| SCHEMBL13340331 | 0.89 | OPRM1 (0.35) | HPGDKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL13340258 | 0.88 | PDE6D (0.37) | HPGDPDE6DKDM4EALDH1A1MAPT | |
| SCHEMBL13340304 | 0.86 | PDE6D (0.38) | PDE6DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100108997-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-05-06 | — | — | US | disclosed |
| US-20100108997-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-05-06 | — | — | US | disclosed |
| EP-2175005-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100108997-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OR10J3, OCIAD1, OCIAD2 | HPGD 3104/4885PDE6D 966/4885TNKS 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.